Erschienen in:
11.10.2018 | Editorial Commentary
Value proposition of PSMA-targeted α–particle radioligand therapy in metastatic prostate cancer
verfasst von:
Hossein Jadvar
Erschienen in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Ausgabe 1/2019
Einloggen, um Zugang zu erhalten
Excerpt
Theranostics is currently experiencing a renaissance since the early days of radioiodine use in thyroid diseases. While there have been prior clinical platforms for theranostics (e.g., lymphoma, neuroblastoma), the recent regulatory approval and reimbursement of paired agents for somatostatin receptor-targeted theranostics of neuroendocrine tumors has helped to enrich the field [
1]. Exciting developments are currently underway in theranostics of metastatic castrate-resistant prostate cancer (mCRPC), with prostate-specific membrane antigen (PSMA) as the biological target. Despite some limitations with nonspecificity, small molecule inhibitors binding to the external moiety of PSMA and radiolabeled with
68Ga- (e.g. PSMA-11, PSMA-617, PSMA I&T) or
18F- (e.g. DCFPyL, PSMA-1007) have demonstrated excellent diagnostic imaging performance and competitive advantage over other non-PSMA based radiotracers [
2]. When radiolabeled with β-emitters (e.g.,
177Lu,
131I) or α-emitters (e.g.,
225Ac,
213Bi), particular PSMA-based agents can also be used for targeted radiotherapy of the same metastatic lesions that are identified by the imaging companion agent realizing the bidirectional “see & treat” concept [
3‐
9]. …